Fibrosing ILD Biomarkers That Rule Acceleration

Host-microbiome Interactions in the Quest for Fibrosing ILD Biomarkers That Rule Acceleration

FIBRALUNG is a prospective cohort study with biobank of samples from patients with pulmonary fibrosis, aiming to explore the molecular determinants of different clinical outcomes, acute exacerbations and mortality. We expect to gain deeper insight into fibroproliferative common pathways, particularly between idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis, paving the way for new biomarkers that reflect the progressive phenotype, that eventually will support new targeted therapies.

Other idiopathic interstitial pneumonias, connective tissue disease-related interstitial lung diseases and sarcoidosis patients will be also recruited and their biological samples stored for further analyses.

Inclusion Criteria:

• Patients aged between 18-80 years
• People undergoing blood collection, lung biopsy and/or BAL as part of their diagnostic workup
• Willingness to undergo the follow-up protocol evaluations
• Treatment-naïve for disease-modifying drugs
• An HRCT scan performed within the last 12 months showing ≥10% fibrosis extent of the lungs

Exclusion Criteria:

• People who cannot give informed consent
• Pregnancy